SenesTech Gelecekteki Büyüme

Future kriter kontrolleri 2/6

SenesTech kazanç ve gelirinin sırasıyla yıllık 16.7% ve 44.5% oranında artması tahmin edilirken, EPS'nin yıllık 63.5% oranında büyümesi bekleniyor.

Anahtar bilgiler

16.7%

Kazanç büyüme oranı

63.5%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	21.5%
Gelir büyüme oranı	44.5%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	28 Dec 2023

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:SE81 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	8	-6	-4	N/A	1
12/31/2025	5	-7	-6	N/A	1
12/31/2024	2	-8	-7	N/A	1
12/31/2023	1	-8	-2	N/A	1
9/30/2023	1	-8	-8	-8	N/A
6/30/2023	1	-9	-8	-8	N/A
3/31/2023	1	-9	-9	-9	N/A
12/31/2022	1	-10	-9	-9	N/A
9/30/2022	1	-10	-8	-8	N/A
6/30/2022	1	-10	-8	-8	N/A
3/31/2022	1	-9	-8	-8	N/A
12/31/2021	1	-8	-8	-8	N/A
9/30/2021	1	-8	-8	-8	N/A
6/30/2021	0	-8	-8	-8	N/A
3/31/2021	0	-7	-7	-7	N/A
12/31/2020	0	-8	-7	-7	N/A
9/30/2020	0	-9	-8	-7	N/A
6/30/2020	0	-10	-8	-8	N/A
3/31/2020	0	-10	-8	-8	N/A
12/31/2019	0	-10	-8	-8	N/A
9/30/2019	0	-10	-8	-8	N/A
6/30/2019	0	-10	-9	-8	N/A
3/31/2019	0	-12	-9	-9	N/A
12/31/2018	0	-12	-9	-9	N/A
9/30/2018	0	-12	-9	-9	N/A
6/30/2018	0	-12	-8	-8	N/A
3/31/2018	0	-11	-9	-8	N/A
12/31/2017	0	-12	-10	-9	N/A
9/30/2017	0	-14	-11	-10	N/A
6/30/2017	0	-13	N/A	-10	N/A
3/31/2017	0	-12	N/A	-9	N/A
12/31/2016	0	-11	N/A	-7	N/A
9/30/2016	0	-14	N/A	-5	N/A
6/30/2016	0	-20	N/A	-4	N/A
3/31/2016	0	-20	N/A	-4	N/A
12/31/2015	0	-18	N/A	-4	N/A
12/31/2014	0	-7	N/A	-3	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: SE81 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: SE81 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: SE81 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: SE81 şirketinin gelirinin (yıllık 44.5% ) German pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: SE81 şirketinin gelirinin (yıllık 44.5% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: SE81 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

SenesTech Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

No longer forecast to breakeven

Forecast to breakeven in 2025

Recent updates

SenesTech Launches Evolve Rodent Birth Control on Walmart Marketplace

SenesTech, Inc. to Report Q3, 2024 Results on Nov 12, 2024

SenesTech, Inc.'s Evolve™ Registers in Hong Kong; Offering a Revolutionary Non-Lethal Rodent Control Solution

SenesTech Receives Notification from Nasdaq Due to Non-Compliance with Nasdaq’s Audit Committee Requirements as Set Forth in Nasdaq Listing Rule 5605

SenesTech, Inc. to Report Q2, 2024 Results on Aug 08, 2024

SenesTech, Inc. has filed a Follow-on Equity Offering in the amount of $1.575944 million.

SenesTech, Inc., Annual General Meeting, Jul 11, 2024

SenesTech, Inc. to Report Q1, 2024 Results on May 09, 2024

Nasdaq Determines SenesTech Eligible for an Additional 180 Calendar Day Period, or Until August 19, 2024, to Regain Compliance with the Minimum Bid Price Requirement

SenesTech, Inc. to Report Q4, 2023 Results on Feb 21, 2024

SenesTech Partners with Global Leader in Irrigation Solutions to Expand Evolve Soft Bait to Open Field Agriculture Applications

SenesTech's ContraPest Registered for Use in Puerto Rico to Combat Rat Infestations

SenesTech, Inc. has completed a Follow-on Equity Offering.

SenesTech, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

SenesTech Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Third quarter 2023 earnings released: US$0.47 loss per share (vs US$4.33 loss in 3Q 2022)

SenesTech, Inc. to Report Q3, 2023 Results on Nov 09, 2023

SenesTech Taking Orders for Evolve™ Soft Bait for Rodent Fertility Control

SenesTech, Inc. Launches Evolve Soft Bait for Rodent Fertility Control

SenesTech Receives Non-Compliance Letter from Nasdaq

Second quarter 2023 earnings released: US$0.70 loss per share (vs US$4.21 loss in 2Q 2022)

SenesTech, Inc. to Report Q2, 2023 Results on Aug 10, 2023

SenesTech, Inc. Launches Isolate Bait System for Contrapest

First quarter 2023 earnings released: US$0.001 loss per share (vs US$3.82 loss in 1Q 2022)

SenesTech, Inc. to Report Q1, 2023 Results on May 11, 2023

No longer forecast to breakeven

Senestech Names Nicole Williams as Chief Revenue Officer

Third quarter 2022 earnings released: US$0.22 loss per share (vs US$0.18 loss in 3Q 2021)

SenesTech, Inc. Announces Executive Changes

SenesTech, Inc. to Report Q3, 2022 Results on Nov 14, 2022

SenesTech Announces Resignation of K.C. Kavanagh as Member of Board of Directors

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.14 loss in 2Q 2021)

SenesTech, Inc. to Report Q2, 2022 Results on Aug 11, 2022

SenesTech, Inc. Announces its New Elevate Bait System with ContraPest Now Available in California

SenesTech, Inc. Announces its New Elevate Bait System with ContraPest Available for Sale

First quarter 2022 earnings released: US$0.19 loss per share (vs US$0.22 loss in 1Q 2021)

SenesTech, Inc. to Report Q1, 2022 Results on May 12, 2022

SenesTech, Inc., Annual General Meeting, Jun 23, 2022

Full year 2021 earnings released: US$0.74 loss per share (vs US$2.79 loss in FY 2020)

High number of new directors

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.56 loss in 3Q 2020)

Independent Director recently bought €195k worth of stock

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.59 loss in 2Q 2020)

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.22 loss per share (vs US$1.70 loss in 1Q 2020)

Full year 2020 earnings released: US$2.64 loss per share (vs US$7.69 loss in FY 2019)

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin